New York, New York, June 30, 2015 -- Lauren Sciences LLC, the private New York biotechnology company developing breakthrough V-Smart™ Nanomedicines for brain diseases, announced today the award of a grant by Voices Against Brain Cancer (VABC). VABC funding will support the development of a V-Smart™ for glioblastoma multiforme (GBM). The future success of V-Smart™ for GBM should provide an effective new treatment for GBM patients.
V-Smart™ for GBM will target and deliver a known chemotherapeutic that has proven potential to treat GBM, but does not cross the blood brain barrier (BBB) on its own, to GBM tumor cells. V-Smart™ Nanomedicines are designed to target and deliver therapeutics across the BBB and into selective brain cells both non-invasively and effectively. V-Smart™ for GBM will solve the problem that many potential therapeutic agents for GBM do not cross the BBB.
"We thank Voices Against Brain Cancer for their award," said Susan Rosenbaum, J.D., Founder, Chairman and Chief Executive Officer of Lauren Sciences. "VABC's grant is recognition of our successes to date, and investment in the future success of V-Smart™ for GBM as a transformative therapeutic for brain cancer patients."
"A major goal of VABC is to invest in cutting edge developments that can have a monumental impact on the course of brain cancer," said Michael Klipper, Chairman of VABC. "Certain anti-cancer agents have shown potential, but, because they cannot get into the brain by existing oral or i.v. delivery, fall short for patients. This challenge represents a critical unmet need in the field of brain cancer. V-Smart™ for GBM can solve the problem that many potential therapeutic agents for GBM do not cross the BBB."
"V-Smart™ for GBM, formulated with a potent anti-tumor agent, has promise as an effective new treatment for GBM patients," said Irwin Hollander, Ph.D., Vice President, Research and Development, Lauren Sciences. "Our goal for this new V-Smart™ drug is to stop progression of, or eradicate, GBM, unlike standard treatments that, in the vast majority of patients, merely delay disease progression. We anticipate future efficacy studies of V-Smart™ for GBM in GBM pre-clinical model and, thereafter, clinical studies in patients. Our goal is clinical validation and approval of this V-Smart™ for GBM."
###
About V-Smart™ Nanomedicines for Brain Diseases
V-Smart™ Nanomedicines can encapsulate therapeutic agents, cross the blood brain barrier (BBB), target sites in the brain, selectively release therapeutic agents at target sites and be administered systemically. A considerable number of therapeutic agents, with the potential to treat or cure disease, do not cross the BBB. V-Smart™ Nanomedicines, with their proven ability to deliver into the brain non-invasively and be effective, can uniquely improve patients' lives. V-Smart™ Nanomedicines represent groundbreaking innovation, and have won recognition for their competitive advantages, as demonstrated by compelling data.
About Lauren Sciences LLC
Lauren Sciences is a private, New York biotechnology company that leads in breakthrough innovation with the development of transformative V-Smart™ Nanomedicines for brain diseases, including CNS, neurodegenerative and rare/orphan brain diseases, such as GBM, NPC, ALS, Neuro-AIDS, Parkinson's, Alzheimer's and LSDs, among others, as well as neurodevelopmental and psychiatric disorders. Most therapeutic agents with the potential to treat or cure these diseases do not cross the BBB. Innovative V-Smart™ Nanomedicines, with their proven ability to encapsulate therapeutic agents, cross the BBB, target and deliver to sites in the brain, selectively release at target sites and be administered systemically, uniquely solve the problem. Lauren Sciences has advanced development of its proprietary V-Smart™ pipeline with disease foundations, and has been awarded grants by Voices Against Brain Cancer, Dana's Angels Research Trust and The Hide and Seek Foundation in collaboration with SOAR-NPC, The ALS Association, The Campbell Foundation for HIV/AIDS Research and The Michael J. Fox Foundation for Parkinson's Disease, among others. Lauren Sciences also has strategic partnerships with major pharmaceutical companies, collaborations with prestigious U.S. university medical centers, invitations to present V-Smart™ research at scientific conferences, features in industry research reports, a world-wide patent portfolio and extensive publications on V-Smart™ in peer-reviewed scientific journals. Lauren Sciences research team and laboratories are at Ben-Gurion University in Israel, where the V-Smart™ technology was invented.
About Voices Against Brain Cancer
Voices Against Brain Cancer's (VABC) mission is to find a cure for brain cancer and brain tumors by advancing scientific research, increasing awareness, creating a brain cancer and tumor community, and supporting patients, their families and caregivers afflicted with this devastating disease. VABC has a wide variety of initiatives in motion for brain cancer research, awareness and support. The organization's research grants fund cutting-edge programs that will have a monumental impact on the diagnosis and treatment of brain cancer and brain tumors. Currently, these grants are being funded at numerous esteemed institutions including: Baylor, Brookhaven, Cleveland Clinic, Columbia, Cornell, Duke, Harvard, Hofstra, Johns Hopkins, MD Anderson, Memorial Sloan Kettering, New York U., North Shore LIJ, Northwestern, Ohio State, Rush, Stony Brook, U. of California, U. of Chicago, U. of Michigan, U. of Pittsburgh, U. of Texas, U. of Virginia, Vanderbilt, Wake Forest, Washington U., Yale and more. VABC extends throughout the international community and funds research in countries such as Australia, Canada, Israel, Spain and more. As part of the Foundation's commitment to "leave no stone unturned" in the search for a cure, VABC supports Cannabis Research and the exploration of the potential risks associated with Mobile Phone Radiation. For more information, please visit: http://www.voicesagainstbraincancer.org.